Orange Book product · Brand (NDA)
HYCODAN
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
At a glance
Jul 26, 1988
Approved
Brand (NDA)
Application
AA
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 26, 1988
38 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
Strength
1.5MG/5ML;5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
SYRUP
Route
ORAL
TE code
AA
Application
NDA 005213
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2019HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 210663 · SANKALP LIFECARE
- 2017HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEGeneric (ANDA)
ANDA 207176 · AVANTHI INC
- 2017HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 204765 · SCIEGEN PHARMS
- 2017HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 207487 · ABHAI LLC
- 2017HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 205731 · PADAGIS US
- 2017HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 203535 · NOVEL LABS INC
- 2011HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEGeneric (ANDA)
ANDA 091528 · NOVEL LABS INC
- 2008HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 040613 · GENUS LIFESCIENCES
- 2000HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEGeneric (ANDA)
ANDA 040295 · ACTAVIS ELIZABETH
- 1999HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEGeneric (ANDA)
ANDA 040285 · IVAX SUB TEVA PHARMS
- 1985TUSSIGONGeneric (ANDA)
ANDA 088508 · KING PHARMS
- 1985HYDROPANEGeneric (ANDA)
ANDA 088066 · HALSEY
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

